



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Leandrou, S., Lamnisos, D., Mamais, I., Kyriacou, P. A., Pattichis, C. S. & Alzheimer's Disease and Neuroimaging Initiative, (2020). Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex. *Frontiers in Aging Neuroscience*, 12, 176. doi: 10.3389/fnagi.2020.00176

This is the published version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/24638/>

**Link to published version:** <https://doi.org/10.3389/fnagi.2020.00176>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.





# Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex

Stephanos Leandrou<sup>1,2\*</sup>, Demetris Lamnisos<sup>1</sup>, Ioannis Mamais<sup>1</sup>,  
Panicos A. Kyriacou<sup>2</sup> and Constantinos S. Pattichis<sup>3,4</sup> for the Alzheimer's Disease and  
Neuroimaging Initiative†

<sup>1</sup> School of Science, European University Cyprus, Nicosia, Cyprus, <sup>2</sup> School of Mathematical Sciences, Computer Science and Engineering, City, University of London, London, United Kingdom, <sup>3</sup> Department of Computer Science, University of Cyprus, Nicosia, Cyprus, <sup>4</sup> Research Centre on Interactive Media, Smart Systems and Emerging Technologies (RISE CoE), Nicosia, Cyprus

## OPEN ACCESS

### Edited by:

Ashok Kumar,  
University of Florida, United States

### Reviewed by:

Sachchida Nand Rai,  
University of Allahabad, India  
Patrizia Giannoni,  
University of Nimes, France

### \*Correspondence:

Stephanos Leandrou  
s.leandrou@euc.ac.cy

† A portion of data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

**Received:** 04 March 2020

**Accepted:** 20 May 2020

**Published:** 02 July 2020

### Citation:

Leandrou S, Lamnisos D, Mamais I, Kyriacou PA and Pattichis CS (2020) Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex.  
*Front. Aging Neurosci.* 12:176.  
doi: 10.3389/fnagi.2020.00176

Alzheimer's disease (AD) brain magnetic resonance imaging (MRI) biomarkers based on larger-scale tissue neurodegeneration changes, such as atrophy, are currently widely used. Texture analysis evaluates the statistical properties of the tissue image quantitatively; therefore, it could detect smaller-scale changes of neurodegeneration. Entorhinal cortex is the first region affected, and no study has investigated texture analysis on this region before. This study aims to differentiate AD patients from Normal Control (NC) and Mild Cognitive Impairment (MCI) subjects using entorhinal cortex texture features. Furthermore, it was evaluated whether texture has association to MCI beyond that of volume, to evaluate if atrophy development may precede. Texture features were extracted from 194 NC, 200 MCI, 84 MCI who converted to AD (MCIc), and 130 AD subjects. Receiving operating characteristic curves determined the performance of the various features in discriminating the groups, and a predictive model was used to predict conversion of MCIc subjects to AD. An area under the curve (AUC) of 0.872, 0.710, 0.730, and 0.764 was seen between NC vs. AD, NC vs. MCI, MCI vs. MCIc, and MCI vs. AD subjects, respectively. Including entorhinal cortex volume improved the AUCs to 0.914, 0.740, 0.756, and 0.780, respectively. For the disease prediction, binary logistic regression was applied on five randomly selected test groups and achieved on average AUC's of 0.760 and 0.764 on the training and validation cohorts, respectively. Entorhinal cortex texture features were significantly different between the four groups and in many cases provided better results compared to other methods such as volumetry.

**Keywords:** Alzheimer's disease, mild cognitive impairment, entorhinal cortex, magnetic resonance imaging, texture

## INTRODUCTION

Alzheimer's disease (AD) represents the first disease in the top 10 disease leading cause of death in the United States (US), and it cannot be prevented, slowed, or cured. It represents the most common form of dementia, which affects memory, language, and other cognitive skills and eventually leads to an inability of everyday activities. Despite continuous advances in exploring the nature of AD,

according to the World Health Organization (WHO), there are 47 million patients worldwide, and by 2030, this number is projected to increase to 75 million.

There are still many unresolved issues regarding the pathophysiology of this highly heterogeneous disease in terms of diagnosis and follow-up. In an attempt to understand better the disease, studies have been examining the neuropathology and cognitive impairment in animal models such as transgenic mice (see Kitazawa et al., 2012; Saito et al., 2014 for a review). However, it seems that AD is a uniquely human disease. With no doubt, animal models offer the advantage of *in vivo* testing, which in humans is available only post-mortem; however, they lack main disease pathological features such as neuronal loss or neurofibrillary tangle (NFT) development, which is the neuropathological hallmark of AD (Drummond and Wisniewski, 2017). The diagnosis of the disease still remains probable and only post-mortem biopsy can confirm AD as it reveals deposits of amyloid- $\beta$  (A $\beta$ ) plaque deposition and tau protein (NFTs) in the brain tissue (Braak and Braak, 1997a). However, due to brain inaccessibility, the diagnosis is based on other factors such as medical and family history, input from the family members regarding the behavior of the subject, blood test, imaging, and cognitive tests. Cognitive tests such as the Mini Mental State Examination (MMSE) (Folstein et al., 1975) and the Clinical Dementia Rating (CDR) (Morris, 1993) represent two of the most commonly used tests in the assessment of AD, and they evaluate memory and language abilities. However, an important limitation of clinical and cognitive assessment is the diagnosis of probable AD after structural changes have occurred within the brain (Braak and Braak, 1991, 1996; Morris et al., 1996). Jack et al. (2004) showed that brain atrophy on structural magnetic resonance imaging (MRI) was detected more consistently than decline on cognitive scores in patients with AD. Furthermore, when cognitive assessment is not used in combination with other biomarkers, the former suffers from low sensitivity (Dukart et al., 2016).

Indeed, decades before the first clinical symptoms become apparent, there is an inevitable progression of atrophy, which initially affects the medial temporal lobe (MTL) (Scahill et al., 2002; Petrella et al., 2003; Jack et al., 2004). MTL is highly associated with memory, and as the neurons get affected, cognitive and functional deficits start to appear. Post-mortem studies (Braak and Braak, 1997b; Kordower et al., 2001) have implicated entorhinal cortex as an early site of involvement in AD followed by the hippocampus, the amygdala, and the parahippocampal gyrus (Dickerson et al., 2001; Killiany et al., 2002; Squire et al., 2004).

Mild cognitive impairment (MCI) represents the transitional stage between normal aging and AD, and it cannot be easily identified by cognitive tests. MCI subjects may have decreased memory function beyond the normal level based on a given person's age and education; however, they do not fulfill the criteria for dementia, as their cognitive function is comparable to Normal Control (NC) subjects. Most of these subjects will remain stable even after 10 years of follow-up (Mitchell and Shiri-Feshki, 2009), and only ~15% will progress to AD (Farias et al., 2009).

Therefore, due to cognitive assessment limitations especially for MCI subjects, the research community has been actively searching for diagnostic imaging biomarkers especially the ones derived from quantitative T1-weighted MRI. The importance of structural MRI in the assessment of AD was underlined by its inclusion in the new diagnostic criteria (Dubois et al., 2007) along with temporoparietal hypometabolism as seen in positron emission tomography (PET) (Mosconi et al., 2008), positivity on amyloid imaging as seen in PET (Johnson et al., 2013), and abnormal neuronal cerebrospinal fluid (CSF) biomarkers (tau and/or A $\beta$ ) (Brier et al., 2016; Bjerke and Engelborghs, 2018; Blennow and Zetterberg, 2018). However, PET studies are not easily accessible, due to several factors such as cost, radiopharmaceutical limitations (availability, targeting amyloid or tau proteins), and exposure to ionizing radiation. On the other hand, structural MRI has no ionizing radiation; thus, it is preferable in longitudinal investigations, and it provides high-resolution images. However, radiologists cannot perceive subtle changes of neurodegeneration, especially in the early stages of the disease by the naked eye observation. Even if they could, without any quantitative measurements, it would be impossible to predict the patient's progress.

Therefore, research on quantitative MRI-derived biomarkers of AD is an active research area, which can reveal the cerebral atrophy and they are used as a biomarker in the assessment of AD. In the literature, several MRI quantitative methods are described for use in the assessment of AD. Such methods are: (i) voxel-based morphometry (VBM), which describes global changes or atrophy of the deep cerebral structures (ii) volume analysis (iii) thickness analysis (iv) shape, and (v) texture analysis. Volumetry remains the most popular technique to assess AD especially in the area of MTL (Jack et al., 1999; Killiany et al., 2000; Dickerson et al., 2001; Pennanen et al., 2004). Apart from the MTL, other studies chose to assess the whole brain (Misra et al., 2009; Plant et al., 2010), although the cortex is affected in later stage (Braak and Braak, 1991). Multimethod studies (Cuingnet et al., 2011; Wolz et al., 2011; Da et al., 2014) combined biomarkers for a better understanding of the disease pathophysiology and heterogeneity.

The accumulation of NFTs and A $\beta$  plaques is present prior to atrophy, and these plaques could affect image intensity structure and distribution. Texture analysis statistical properties of the image intensities might represent changes in MRI image pixel intensity due to NFTs and A $\beta$  plaques. Furthermore, MRI biomarkers based on texture might be able to detect earlier stages of AD than biomarkers that use larger-scale changes, such as thickness or atrophy. The establishment of such biomarkers will allow the identification of individuals with MCI at an earlier stage. This might lead to a better management of the MCI group targeting in slower progression or even prevention to conversion to AD.

Although hippocampus represents the most established region of interest (ROI) used in the assessment of AD, the earlier involvement of the entorhinal cortex was proved by many studies (Gómez-Isla et al., 1997; Juottonen et al., 1999; Galton et al., 2001; Killiany et al., 2002; Busatto et al., 2003; de Toledo-Morrell et al., 2004; Tapiola et al., 2008). In two comprehensive

reviews (Zhou et al., 2016; Leandrou et al., 2018), the authors concluded that structural changes in the early stages of the disease are more pronounced in the entorhinal cortex. **Table 1** tabulates studies that used entorhinal cortex in the assessment of AD. Furthermore, for the disease prediction, entorhinal cortex provided better predictive accuracies compared to hippocampus. Although volumetry represents the most commonly used method to date, there is lack of research in the assessment of AD using texture analysis. The study of Sørensen et al. (2015), found that hippocampal texture was superior to volume reduction for the disease prediction. Therefore, we hypothesized that through the earlier involvement of entorhinal cortex and by using texture, it is likely to detect microscopic alterations of the disease before atrophy spreads.

Since we wanted to evaluate the classification and prediction value of MRI, other related to AD features such as CSF Tau, A $\beta$  biomarkers, or ApoE genotyping were not included in the analysis, as they are not generally available in population samples. However, age and gender as main risk factors for developing AD were included.

To the best of our knowledge, this is the first study that used texture analysis on the entorhinal cortex. The main objective in this study was to determine whether MRI entorhinal cortex texture features could detect early cognitive decline in MCI and AD subjects. In addition, we compared entorhinal cortex results to the gold standard method, hippocampal volume, to evaluate which method could provide the best results. We emphasize here that the goal of our research was to investigate the usefulness of entorhinal cortex texture in AD assessment. Then, through a follow-up period of 18 months, we did a comparison between volume and texture measures to evaluate the hypothesis that

texture changes may precede the development of atrophy. Finally, we evaluated if entorhinal cortex texture features can be used in the prediction of conversion from MCI to AD.

## MATERIALS AND METHODS

### The Alzheimer's Disease Neuroimaging Initiative

Data were acquired from the Alzheimer's Disease Neuroimaging Initiative (ADNI).<sup>1</sup> The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and non-profit organizations as a public-private partnership. The goal of the ADNI study is to determine biological biomarkers of AD through neuroimaging, genetics, neuropsychological tests, and other measures in order to develop new treatments and monitor their effectiveness, and lessen the time of clinical trials.

### Subjects

All subjects selected for this study were from standardized data collections (see <http://adni.loni.usc.edu/methods/mri-analysis/adni-standardized-data/>) and specifically from the ADNI-1 Complete 2 and 3 year 1.5 Tesla datasets. All data acquired as part of this study are publicly available.<sup>2</sup> Enrolled subjects were all between 55 and 90 years of age, and each subject was willing, able to perform all test procedures described in the protocol, and had

<sup>1</sup><http://adni.loni.usc.edu/>

<sup>2</sup><http://adni.loni.usc.edu/data-samples/>

**TABLE 1 |** Selected quantitative magnetic resonance imaging (MRI) studies where entorhinal cortex was used for the classification of AD and the prediction of conversion from MCI to AD.

Author	Data type	Classification	ROI	Acc.	Se.	Sp.	Description
<b>Classification studies</b>							
Juottonen et al. (1999)	Volume	NC vs. AD	Hip. Erc.	86% 87%	80% 80%	91% 94%	Both hippocampus and entorhinal cortex had the same discriminative power.
Pennanen et al. (2004)	Volume	NC vs. MCI	Hip. Erc.	60% 66%	57% 65%	62% 70%	Between NC and MCI subjects entorhinal cortex atrophy was more pronounced and provided better classification.
Ryu et al. (2017)	Volume	SMI vs. NC	Hip Erc.	NA	67% 78%	85% 93%	Subjects with SMI had lower Erc. volumes than NC, whereas no differences in Hip volume were seen
<b>Prediction of conversion from MCI to AD</b>							
Killiany et al. (2002)	Volume	0 vs. 36 months	Hip. Erc.	NA 84%	NA	NA	Entorhinal cortex differentiated MCI subjects that developed AD, whereas hippocampus did not
deToledo-Morrell et al. (2004)	Volume	0 vs. 36 months	Hip. Erc.	NA 93%	NA	NA	Entorhinal cortex provided better predictive accuracy from hippocampus
Devanand et al. (2007)	Volume	0 vs. 36 months	Hip. Erc.	79% 80%	61% 63%	NA	Entorhinal cortex had more atrophy rates than hippocampus for MCIc
Bakkour et al. (2009)	Thickness	0 vs. 36 months	Cortex	NA	83%	65%	Entorhinal cortex volume may be a better predictor in people with MCI rather than hippocampal volume
Eskildsen et al. (2013)	Thickness	0 vs. 36 months	Cortex	67%– 76%	NA	NA	Longitudinal measures in MCI subjects showed that entorhinal cortex was affected first, followed by hippocampus

SMI, subjective memory impairment; NC, normal controls; MCI, mild cognitive impairment; MCIc, mild cognitive impairment converter; AD, Alzheimer's disease; ROI, region of interest; Acc., accuracy; Se, sensitivity; Sp, specificity.



a study partner who is able to provide an independent evaluation of functioning. Overall, 455 subjects were included in the study: 153 NC (73 males and 80 females), 141 MCI (95 males and 46 females), 77 MCI subjects that converted to AD (MCIc; 43 males and 34 females), and 84 AD (40 males and 44 females).

## Cognitive Measures

All subjects underwent through clinical and cognitive assessment at the time of baseline scan to determine their diagnosis. Inclusion criteria for NC were MMSE scores between 24 and 30; CDR of zero; absence of depression, MCI, and dementia. Inclusion criteria for MCI were MMSE scores between 24 and 30; CDR of 0.5; objective memory loss, measured by education adjusted scores on Wechsler Memory Scale Logical Memory II (Elwood, 1991), absence of significant levels of impairment in other cognitive domains, and absence of dementia. Inclusion criteria for AD were MMSE scores between 20 and 26; CDR of 0.5 or 1.0; National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD (McKhann et al., 1984; Dubois et al., 2007). Definitive autopsy-based diagnosis of AD was not possible, and detailed description of inclusion/exclusion criteria can be found in the ADNI protocol.<sup>3</sup>

## MRI Data

All the subjects had a standardized protocol on 1.5-T MRI units from Siemens Medical Solutions and General Electric Healthcare. MR protocols included high-resolution (typically  $1.25 \times 1.25 \times 1.25 \text{ mm}^3$  voxels) T1-weighted volumetric 3D sagittal magnetization prepared rapid gradient-echo (MPRAGE) scans. MRI data acquisition techniques were standardized across different sites according to the ADNI protocol.<sup>4</sup>

## Segmentation Algorithm and Volumetry

ROI segmentation was performed using the FreeSurfer image analysis suite (Massachusetts General Hospital, Boston, MA, United States), which is documented and freely available for download online.<sup>5</sup> The FreeSurfer pipeline conforms the MRI scans to an isotropic voxel size of  $1 \text{ mm}^3$ , and the MRI intensity was normalized using the automated N3 algorithm (Sled et al., 1998) followed by skull stripping and neck removal. Details of these have been discussed in previous publications (Fischl et al., 2002, 2004). In brief, this multistep pipeline includes motion correction, automated Talairach transformation, first normalization of voxel intensities, removal of the skull, linear volumetric registration, intensity normalization, non-linear volumetric registration, volumetric labeling, second normalization of voxel intensities, and white matter segmentation. Output includes segmentation of subcortical structures, extraction of cortical surfaces, cortical thickness estimation, spatial normalization onto the FreeSurfer surface template (FsAverage), and parcellation of cortical regions.

Hippocampal and entorhinal cortex volumes were computed using FreeSurfer segmentations given that this is an established method. Cy-Tera supercomputer of the Cyprus Institute was used to run FreeSurfer.

## Texture Analysis

Texture features were calculated using KNIME Analytics platform (Berthold et al., 2008). The following Haralick texture features (Haralick et al., 1973) were computed: angular second moment (ASM), contrast, correlation, variance, sum average, sum variance, entropy, and cluster shade, and their average in four directions ( $0^\circ$ ,  $45^\circ$ ,  $90^\circ$ ,  $135^\circ$ ) was used.

## Statistical Analysis

Demographic data along with cognitive tests, texture and volume features of subjects at baseline scans were compared with one-way ANOVA to determine statistical differences between the groups (NC, MCI, MCIc, AD). Then, *post-hoc* tests using the Bonferroni correction were applied to determine if there were significant differences in texture features between the groups. There were no outliers in the data, as assessed by inspection of a boxplot.

Texture features and volume were combined as predictor variables in a logistic regression model in order to investigate the potential of combined value of the two MRI biomarkers. Backward elimination methods were used to select the most suitable variables. Apart from texture and volume, we included age and gender as covariates. Through receiving operating characteristic (ROC) curves, we determined the performance of the various variables, and their ability to discriminate NC from MCI and AD subjects, as well as to classify the conversion status. The resulting area under the curve (AUC) was used to determine the capability for diagnosis. The significance of an AUC was determined using DeLong, Delong, and Clarke-Pearson's test (DeLong et al., 1988).

Then, through a repeated measures ANOVA, we compared entorhinal cortex and hippocampal volume changes with texture changes within 18 months and evaluated if there were significant texture changes during follow-up period. Data were checked for outliers and normal distribution, as assessed by boxplot and Shapiro-Wilk test ( $p > 0.05$ ). When sphericity was violated, as assessed by Mauchly's test, the Greenhouse-Geisser correction was applied. Then, *post-hoc* tests using the Bonferroni correction was used to compare the volume and texture changes.

To evaluate the prognostic power of our model, we also used AUC curves on MCI and MCIc subjects. Specifically, the MCI group was randomly divided into both a training set ( $\sim 70\%$  of the participants) and a trial set ( $\sim 30\%$ ) of the participants. This was iterated five times to provide five unique training and test groups. The training sets were used to fit two binary logistic regression models: the first model included entorhinal cortex volume, MMSE scores, age, and gender as covariates, and the second model had the same features, plus entorhinal cortex texture to determine if the addition of texture-based metrics could improve the accuracy. For a more robust prediction model, the collinearity between the predictor variables was evaluated, and only those for which the collinearity was acceptable were included

<sup>3</sup><http://adni.loni.usc.edu/methods/documents/>

<sup>4</sup><http://adni.loni.usc.edu/methods/documents/mri-protocols/>

<sup>5</sup><http://surfer.nmr.mgh.harvard.edu/>

in the final model. The estimated logistic regression model was then applied to the validation cohorts.

Statistical analysis was performed with IBM SPSS Statistics Version 24 (IBM Corp. Released 2011; IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) or MedCalc Version 19 (MedCalc Software bvba, Ostend, Belgium).<sup>6</sup> The significance level of all statistical tests was set at  $P < 0.05$ .

## RESULTS

Baseline demographics including gender, age, and MMSE scores are shown in **Table 2**. All baseline variables (except the age) were significantly different between the four groups based on one-way ANOVA. Estimations of hippocampal and entorhinal cortex volumes are in cubic millimeter (left and right averaged). As expected, AD patients had smaller volumes than MCI subjects, and both had smaller volumes than NC subjects.

### Between-Group Differences

A one-way ANOVA was conducted to determine if there were significant texture features between the groups for baseline scans (**Table 3**). For NC vs. AD and NC vs. MCI groups, entorhinal cortex revealed statistically significant differences in more features compared to hippocampus. Specifically, hippocampus did not show any significant changes for NC vs. MCI group, apart for volume. However, hippocampal texture revealed statistical significant differences in more features between MCI vs. MCIC group. Between MCI vs. AD, both structures had similar results with entorhinal cortex showing statistically significant differences in the texture feature contrast, correlation, sum variance, and entropy, whereas hippocampus for the texture feature ASM, sum average, and entropy.

### Texture Differences Between Groups – Classification

To determine the classification between the groups, a binary logistic regression model was calculated for each individual variable, and using ROC curves, we determined their AUC. The combination model included raw single MRI variable scores as

well as age and gender as covariates. In most of the cases, all eight texture features revealed significant differences between groups (see **Tables 4–6**). Then, all the variables were combined together, and the backward elimination method selected the more important predictor variables.

For NC vs. AD group, the AUC for entorhinal cortex texture values ranged from 0.540 to 0.824 (**Table 4**). When texture features were combined into a single classification model, the AUC reached 0.872, which was similar to hippocampal volume (AUC 0.869) and entorhinal cortex volume (AUC 0.888). When entorhinal cortex texture and volume were combined, the AUC reached 0.914.

Between NC and MCI subjects, features combination showed a lower AUC (0.710) compared to entorhinal and hippocampal volume (**Table 5**). The entorhinal cortex texture and volume combination raised the AUC to 0.740.

Between MCI and MCIC subjects, features combination provided a higher AUC (0.730), compared to entorhinal cortex and hippocampal volume (**Table 6**). The entorhinal cortex texture and volume combination raised the AUC to 0.756.

Between MCI and AD subjects, features combination showed a higher AUC of 0.764 compared to entorhinal cortex and hippocampal volume (**Table 7**). The entorhinal cortex texture and volume combination raised the AUC to 0.780.

### Measures Between Different MRI Scan Intervals

A one-way repeated measures ANOVA was conducted to determine whether there were statistically significant differences in entorhinal cortex (texture and volume) over the 18-month observation (baseline, 6, 12, and 18 months). For comparison, hippocampal volume was also included in this analysis. At each time point, a diagnosis was made based on the NINCDS-ADRDA Alzheimer's Criteria to identify conversion of MCI to probable AD and vice versa, and only MCI and MCIC subjects were included in this part of the analysis. Specifically, longitudinal data of 141 MCI and 77 MCIC subjects were included in this analysis. The means and standard deviations for volume are presented in **Table 8** and for texture in **Table 9**. We reported the  $F$ -statistic from the repeated measures ANOVA test as  $F(df_{\text{time}}, df_{\text{error}}) = F\text{-value}$ ,  $P = P\text{-value}$ .

<sup>6</sup><https://www.medcalc.org>; 2019

**TABLE 2** | Baseline demographics and hippocampal and entorhinal cortex volume.

Variables at baseline (mean $\pm$ SD)	Diagnosis group				P-value
	NC (n = 194)	MCI (n = 200)	MCIC (n = 84)	AD (n = 130)	
Sex (M/F)	96/98	127/73	49/35	60/70	0.003
Age	76.17 (5.20)	74.74 (7.18)	74.88 (7.30)	76.01 (7.35)	0.111
MMSE score	29 (1.0)	27 (1.82)	26 (1.84)	23 (2.16)	<0.001
CDR	0.0 (0.00)	0.50 (0.04)	0.50 (0.00)	0.75 (0.25)	<0.001
Entorhinal cortex volume (mm <sup>3</sup> )	1,930 (284)	17,191,723 (384)	154,410 (338)	1,417 (348)	<0.001
Hippocampal volume (mm <sup>3</sup> )	3,539 (413)	3,243 (461)	2,941 (461)	2,892 (474)	<0.001

NC, normal controls; MCI, mild cognitive impairment; MCIC, mild cognitive impairment converter; AD, Alzheimer's disease; MMSE, mini-mental status examination; CDR, clinical dementia rating; SD, standard deviation.

**TABLE 3 |** Mean differences at baseline scans for entorhinal cortex and hippocampus.

Group	Mean difference (SE)							
	Entorhinal cortex				Hippocampus			
	NC vs. AD	NC vs. MCI	MCI vs. MCIC	MCI vs. AD	NC vs. AD	NC vs. MCI	MCI vs. MCIC	MCI vs. AD
<b>Texture features</b>								
ASM	−0.017* (0.005)	−0.01 (0.004)	−0.007 (0.006)	−0.006 (0.005)	−0.013* (0.004)	−0.008 (0.004)	−0.023* (0.005)	−0.023* (0.005)
Contrast	−0.243* (2.60)	−7.73* (2.27)	−7.36 (2.93)	−16.60* (2.60)	−2.0 (2.36)	−3.61 (2.11)	−4.62 (2.70)	−5.60 (2.32)
Correlation	−0.051* (0.005)	−0.017* (0.004)	−0.013 (0.005)	−0.034* (0.005)	−0.0004 (0.005)	−0.0004 (0.005)	−0.016 (0.007)	−0.001 (0.005)
Variance	−0.201 (1.14)	−1.11 (1.01)	−0.780 (1.30)	−0.910 (1.14)	−2.40 (2.80)	−4.90 (2.46)	−13.0* (2.20)	−7.30 (2.77)
Sum average	−1.44* (0.365)	−0.590 (0.324)	−0.821 (0.414)	−0.853 (0.361)	−1.64* (0.560)	−0.823 (0.498)	2.40* (0.640)	−2.47* (0.556)
Sum variance	−27.70* (4.15)	−12.28* (3.68)	−2.18 (4.80)	−15.41* (4.14)	−6.30 (10.0)	−15.20 (8.80)	−41.0* (11.3)	−21.5 (9.80)
Entropy	−0.137* (0.023)	−0.058* (0.020)	−0.060 (0.026)	−0.080* (0.023)	−0.103* (0.028)	−0.034 (0.024)	−0.113* (0.030)	−0.138* (0.026)
Cluster shade	−471 (350)	−260 (312)	−118* (414)	−730 (342)	−1,009 (1,038)	−2,373 (927)	−4,600* (1182)	−3,383 (1,026)
<b>Volumetric features</b>								
Volume	−513* (39.1)	−211* (34.8)	−174* (45.0)	−301* (38.7)	−646* (52.4)	−295* (42.7)	−302* (60.0)	−351* (51)

SE, standard error; ASM, angular second moment; NC, normal controls; MCI, mild cognitive impairment; MCIC, mild cognitive impairment converter; AD, Alzheimer's disease. \*The mean difference is significant at the 0.05 level.

For entorhinal cortex volume in both MCI and MCIC subjects, there was a significant effect for time [ $F(2.837, 383.0) = 45.62$ ,  $P < 0.0005$ ] and [ $F(3, 186) = 45.06$ ,  $P < 0.0005$ ], respectively. Furthermore, the mean difference was statistically significant at the 0.05 level between all-time points for both MCI and MCIC subjects with the exception of 12–18 time points for MCIC subjects. *Post-hoc* tests using the Bonferroni correction showed that entorhinal cortex volume in the MCI subjects was reduced by

an average of  $20 \pm 6.9 \text{ mm}^3$  6 months after the baseline scan, then by an additional  $19 \pm 6.0 \text{ mm}^3$  between 6 and 12 months' time and  $36 \pm 6.1 \text{ mm}^3$  between 12 and 18 months' time. As expected, the entorhinal cortex degeneration was more pronounced in the MCIC subjects. Their entorhinal cortex volume was reduced by an average of  $55 \pm 10.5 \text{ mm}^3$  6 months after the baseline scan, then by an additional  $25 \pm 9.5 \text{ mm}^3$  between 6 and 12 months' time and  $40 \pm 10.3 \text{ mm}^3$  between 12 and 18 months' time.

**TABLE 4 |** Entorhinal cortex texture and volume in classifying NC vs. AD.

NC vs. AD	ROC analysis AUC	95% CI	P-value
<b>Entorhinal cortex</b>			
<b>Texture features</b>			
ASM	0.592	0.529–0.656	0.005
Contrast	0.794	0.743–0.845	<0.001
Correlation	0.824	0.776–0.872	<0.001
Variance	0.524	0.458–0.590	0.475
Sum average	0.620	0.555–0.681	<0.001
Sum variance	0.713	0.653–0.770	<0.001
Entropy	0.685	0.625–0.744	<0.001
Cluster shade	0.540	0.475–0.604	0.238
<b>Volume and thickness</b>			
Erc. volume	0.888	0.847–0.925	<0.001
Erc. thickness	0.809	0.755–0.863	<0.001
<b>Features combination</b>			
Texture (ASM, correlation, variance, sum average, and cluster shade)	0.872	0.828–0.916	<0.001
Texture + Erc. volume	0.914	0.879–0.950	<0.001
<b>Hippocampus</b>			
Hippocampal volume	0.869	0.827–0.912	<0.001

NC, Normal Controls; AD, Alzheimer's disease; ROC, receiver operating characteristic; AUC, area under curve, CI, confidence interval; ASM, angular second moment; Erc, entorhinal cortex.

**TABLE 5 |** Entorhinal cortex texture and volume in classifying NC vs. MCI.

NC vs. MCI	ROC analysis AUC	95% CI	P-value
<b>Entorhinal cortex</b>			
<b>Texture features</b>			
ASM	0.618	0.563–0.674	<0.001
Contrast	0.664	0.611–0.718	<0.001
Correlation	0.671	0.617–0.725	<0.001
Variance	0.604	0.548–0.660	<0.001
Sum average	0.618	0.562–0.674	<0.001
Sum Variance	0.641	0.586–0.695	<0.001
Entropy	0.632	0.577–0.687	<0.001
Cluster shade	0.608	0.551–0.666	<0.001
<b>Volumetric and thickness</b>			
Erc. volume	0.735	0.686–0.784	<0.001
Erc. thickness	0.659	0.604–0.713	<0.001
<b>Features combination</b>			
Texture (ASM, correlation, variance, sum average, and cluster shade)	0.710	0.656–0.762	<0.001
Texture and Erc. volume	0.740	0.689–0.791	<0.001
<b>Hippocampus</b>			
Hippocampal volume	0.762	0.715–0.809	<0.001

NC, normal controls; MCI, mild cognitive impairment; ROC, receiver operating characteristic; AUC, area under curve, CI, confidence interval; ASM, angular second moment; Erc, entorhinal cortex.



**TABLE 6 |** Entorhinal cortex texture and volume in classifying MCI vs. MCIC.

NC vs. MCI	ROC analysis AUC	95% CI	P-value
<b>Entorhinal cortex</b>			
<b>Texture features</b>			
ASM	0.565	0.494–0.637	0.85
Contrast	0.583	0.510–0.657	0.028
Correlation	0.580	0.505–0.654	0.038
Variance	0.531	0.458–0.604	0.037
Sum average	0.591	0.520–0.662	0.036
Sum variance	0.527	0.451–0.603	0.475
Entropy	0.593	0.522–0.662	0.014
Cluster shade	0.696	0.632–0.759	0.032
<b>Volume and thickness</b>			
Erc. volume	0.642	0.573–0.711	<0.001
Erc. thickness	0.670	0.603–0.737	<0.001
<b>Features combination</b>			
Texture (ASM, correlation, variance, sum average, and cluster shade)	0.730	0.665–0.795	<0.001
Texture and Erc. volume	0.756	0.692–0.820	<0.001
<b>Hippocampus</b>			
Hippocampal volume	0.685	0.617–0.753	<0.001

MCIC, mild cognitive impairment converter; ROC, receiver operating characteristic; AUC, area under curve, CI, confidence interval; ASM, angular second moment; Erc, entorhinal cortex.

**TABLE 7 |** Entorhinal cortex texture and volume in classifying MCI vs. AD.

MCI vs. AD	ROC analysis AUC	95% CI	P-value
<b>Entorhinal cortex</b>			
<b>Texture features</b>			
ASM	0.627	0.565–0.690	<0.001
Contrast	0.704	0.646–0.763	<0.001
Correlation	0.725	0.668–0.783	<0.001
Variance	0.624	0.560–0.688	<0.001
Sum average	0.649	0.587–0.711	<0.001
Sum variance	0.658	0.596–0.720	<0.001
Entropy	0.656	0.594–0.718	<0.001
Cluster shade	0.645	0.583–0.706	<0.001
<b>Volume and thickness</b>			
Erc. volume	0.726	0.670–0.781	<0.001
Erc. thickness	0.702	0.642–0.762	<0.001
<b>Features combination</b>			
Texture (ASM, correlation, variance, sum average, and cluster shade)	0.764	0.710–0.818	<0.001
Texture + Erc. volume	0.780	0.728–0.833	<0.001
<b>Hippocampus</b>			
Hippocampal volume	0.711	0.652–0.771	<0.001

MCI, mild cognitive impairment; AD, Alzheimer's disease; ROC, receiver operating characteristic; AUC, area under curve, CI, confidence interval; ASM, angular second moment; Erc, entorhinal cortex.

For hippocampal volume in both MCI and MCIC subjects, there was significant effect for time [ $F(2.748, 376.4) = 41.8$ ,  $P < 0.0005$ ] and [ $F(3, 195) = 21.74$ ,  $P < 0.0005$ ] respectively.

Furthermore, the mean difference was statistically significant at the 0.05 level between all-time points for both MCI and MCIC subjects with the exception of 12–18 time points for MCIC subjects. Interestingly, hippocampal volume reduction in the MCIC subjects was similar to MCI stable subjects. Specifically, *post-hoc* tests using the Bonferroni correction revealed that hippocampal volume in the MCI subjects was reduced by an average of  $49 \pm 12.6 \text{ mm}^3$  6 months after the baseline scan, then by an additional  $45 \pm 11.5 \text{ mm}^3$  between 6 and 12 months' time and  $38 \pm 11.3 \text{ mm}^3$  between 12 and 18 months' time. A similar pattern was seen in MCIC subjects as well as hippocampal volume reduction was  $45 \pm 15.8 \text{ mm}^3$  after 6 months from the baseline scan, and then reduced by an additional  $40 \pm 14.0 \text{ mm}^3$  between 6 and 12 months' time and an additional  $38 \pm 16.6 \text{ mm}^3$  between 12 and 18 months' time.

Remarkably, repeated measures ANOVA in the entorhinal cortex texture features of MCIC subjects revealed that there was significant effect for time for all features (except for cluster shade), whereas in stable MCI subjects, there was significant effect for time only for sum variance and entropy.

## Prediction of Conversion to AD Within 18 Months

To evaluate entorhinal cortex texture in the prediction of conversion from MCI to AD, all the MCI subjects were divided into two categories: the MCI subjects who remained stable and did not convert to AD within 18 months ( $n = 200$ ) vs. the MCIC subjects who converted to AD within 18 months ( $n = 84$ ). First, we run a prediction model, which included entorhinal cortex volume, MMSE scores, and gender with age as covariates. Then, a second model was run where entorhinal cortex texture features (contrast and cluster shade) were included as well, to evaluate if texture metrics could improve accuracy. The selected variables were also evaluated for colinearity between them, and their degree of correlation was acceptable.

Then, the MCI group was divided into a training set ( $\sim 70$ ) and a trial set ( $\sim 30\%$ ). We randomly generated five of these sets, with each training set having a total of  $n = 133$  MCI and  $n = 55$  MCIC, whereas the trial set had total of  $n = 67$  MCI and  $n = 29$  MCIC. Independent sample *t*-test and chi-square analysis showed no statistical difference between the baseline demographics in the training and trial sets in each iteration. For each of the two models, five binary logistic regression models were determined, corresponding to one for each training set (Table 10). The model including texture performed better and achieved AUCs of 0.795, 0.725, 0.745, 0.786, and 0.750, respectively. Then, the logistic regression coefficients from the final model developed from the training cohorts were applied to the validation cohorts, and AUCs of 0.780, 0.780, 0.790, 0.735, and 0.735 were seen.

## DISCUSSION

The main objective of this study was to evaluate entorhinal cortex texture as a new biomarker of AD from T1-weighted MR images. To the best of our knowledge, this is the first study that used texture analysis on the entorhinal cortex for the assessment of

**TABLE 8 |** Statistically significant difference in entorhinal cortex and hippocampal volume over an 18-month intervention.

Within-subjects effects	Entorhinal cortex volumeMean (SD) mm <sup>3</sup>		Hippocampal volumeMean (SD) mm <sup>3</sup>	
	MCI	MCIc	MCI	MCIc
Baseline	1,733 (390)	1,504 (293)	3,263 (483)	2,906 (439)
6 months	1,712 (389)	1,449 (278)	3,213 (487)	2,860 (423)
12 months	1,693 (393)	1,424 (269)	3,168 (496)	2,819 (432)
18 months	1,657 (411)	1,384 (269)	3,129 (487)	2,781 (436)
F-ratio (Time)	$F(2.837, 383) = 45.62, P < 0.0005$		$F(2.748, 376) = 41.8, P < 0.0005$	

MCI, mild cognitive impairment; MCIc, mild cognitive impairment converters; SD, standard deviation.

AD. Thus, our results are not directly compared to the same method and ROI previously used in other AD studies, but mainly to hippocampal volume, which represents the most frequently used method in the assessment of AD. In the analysis, apart from entorhinal cortex texture features, we calculated also its volume, and we combined them in a binary logistic regression model, which included age and gender as covariates.

For entorhinal cortex, one way-ANOVA showed that contrast, correlation, and volume were the features that showed statistical significant differences between all groups and, for hippocampus, sum average, cluster shade, and volume (see **Table 3**). For the NC vs. MCI group, one-way ANOVA showed that were statistically significant differences in more features for the entorhinal cortex compared to the hippocampus, whereas the hippocampus showed significant differences in more features between MCI vs. MCIc group. Perhaps, these differences are correlated with the fact that entorhinal cortex is the region affected first by the disease (Gómez-Isla et al., 1997; Juottonen et al., 1999; Galton et al., 2001; Killiany et al., 2002; Busatto et al., 2003; deToledo-Morrell et al., 2004; Tapiola et al., 2008), whereas the hippocampus is involved in a later stage.

In the literature, the entorhinal cortex and hippocampus have shown a significant role in the assessment of AD (Leandrou et al., 2018). Similarly, in the present study, results of the ROC curve analysis showed that for the entorhinal cortex, there were significant differences between NC subjects and AD patients. Specifically, there were significant texture changes in six texture features (apart from variance and cluster shade), and their combination provided an AUC of 0.872 ( $P < 0.001$ ) for the discrimination between NC and AD subjects (**Table 4**). This was similar to entorhinal cortex or hippocampal volume, which showed AUC of 0.888 ( $P < 0.001$ ) and 0.869 ( $P < 0.001$ ), respectively. When entorhinal cortex texture features and volume were combined into the same model, the diagnostic result was improved, showing an AUC of 0.914 ( $P < 0.001$ ).

Compared to a study that used hippocampal texture such as from Zhang et al. (2012), their classification accuracy reached 96.4%. However, their dataset included severely affected AD subjects (MMSE  $5.53 \pm 4.47$  compared to  $23 \pm 1.9$  for the ADNI data in the present study). Compared to the study of Sørensen et al. (2015), which also used the ADNI dataset, their hippocampal texture achieved an AUC of 0.912 in discriminating NC from AD. On the other hand, the study of Luk et al. (2018) used texture features on the whole brain, and the combination

of hippocampal texture features and volume provides an AUC of 0.924, which was close to our combined model.

Compared to other ADNI volumetric studies where hippocampus was used, NC subjects were classified from AD patients with AUC levels of 0.750–0.887 (Mueller et al., 2010) and 0.810–0.895 when hippocampal subfields only were used (Khan et al., 2015). This is comparable to our hippocampal volume results (AUC 0.869), which is close to entorhinal cortex texture (AUC 0.888). In other studies (Juottonen et al., 1999; Colliot et al., 2008), where both hippocampal and entorhinal cortex volume were used, the classification accuracy ranged between 84 and 86%. In the study of Pennanen et al. (2004), the combination of hippocampal and entorhinal cortex volume provided an accuracy of 91%.

Between NC vs. MCI subjects, the combination of entorhinal cortex texture features in the logistic regression model provided an AUC of 0.710 and their combination with entorhinal cortex volume raised the AUC to 0.740 (**Table 5**). This is comparable to the AUC (0.764) in the study of Sørensen et al. (2015) where hippocampal texture was used. In the study of Hwang et al. (2016) where voxel-based 3DT1W was used on the whole brain, their AUC ranged between 0.682 and 0.713, which was close to our single ROI method. The study by Simoes et al. (2012) used whole brain texture maps reaching a classification accuracy of 87% (Se. 85%, Sp. 95%); however, their analysis was based on 3-Tesla (T) images. Compared to other studies (Pennanen et al., 2004; Colliot et al., 2008) that used hippocampal volume for the discrimination between NC vs. MCI, a classification accuracy close to 66% was achieved.

Between MCI and MCIc subjects, the combination of entorhinal cortex texture features and volume provided an AUC of 0.756, whereas entorhinal cortex or hippocampal volume provided lower AUCs of 0.642 and 0.685, respectively. Our result for this group was similar to the study of Chincarini et al. (2011) where texture features were extracted from defined volumes of interest, mainly from the MTL, and through random forest classifiers, they achieved an AUC of 0.740. These findings suggest that the entorhinal cortex texture changes precede neuronal atrophy of the hippocampus, which is consistent with the most widely used staging scheme proposed by Braak and Braak (1991). Specifically, Stage I is associated with NFT deposition in the entorhinal–perirhinal cortex, and in Stage II, the NFTs become more prominent, and the entorhinal cortex is eventually involved. In Stage III, the entorhinal cortex is fully involved, whereas

Entorhinal cortex texture features – mean (SD)

[illegible]

There are some limitations in the present study. First, the ADNI cohort cannot be generalized to the normal population given that the patient recruitment was targeted toward clinical trials in patients with AD. The baseline demographics of these

**TABLE 10 |** Area under curve in five trials of randomly splitting training (70%) and trial data (30%).

Trial	Entorhinal cortex volume						Entorhinal cortex volume and texture					
	Training cohort			Validation cohort			Training cohort			Validation cohort		
	ROC analysis AUC	(95% CI)	P-value	ROC analysis AUC	(95% CI)	P-value	ROC analysis AUC	(95% CI)	P-value	ROC analysis AUC	(95% CI)	P-value
1	0.760	0.690–0.830	0.000	0.700	0.583–0.814	0.000	0.795	0.728–0.862	0.000	0.780	0.662–0.898	0.000
2	0.673	0.595–0.751	0.001	0.688	0.573–0.804	0.005	0.725	0.649–0.801	0.000	0.780	0.674–0.886	0.001
3	0.663	0.580–0.746	0.04	0.658	0.538–0.778	0.005	0.745	0.770–0.820	0.000	0.790	0.680–0.903	0.001
4	0.662	0.582–0.742	0.000	0.635	0.500–0.772	0.005	0.786	0.712–0.860	0.000	0.735	0.621–0.848	0.001
5	0.647	0.565–0.730	0.001	0.709	0.591–0.827	0.003	0.751	0.675–0.827	0.000	0.735	0.627–0.843	0.001

ROC, receiver operating characteristic; AUC, area under curve, CI, confidence interval.

sample patients do not fit with the actual demographics of the broader population. For example, female/male ratio is poor with almost twice as many males as females especially for MCI subjects. Furthermore, ADNI study does not provide post-mortem pathological confirmation of the clinical status. Therefore, the stable MCI subjects we selected for the present study although did not progress to AD within the followed-up period, they might have developed the disease or other types of dementia in a later stage. Therefore, as in any AD study involving *in vivo* data, the diagnosis of the disease remains probable. Thus, MRI patterns of neurodegeneration found in studies like the present may have uncertainties.

To our knowledge, this is the first study that runs texture analysis on the entorhinal cortex for the assessment of AD to identify texture changes in the classification of MCI and AD subjects. Furthermore, it evaluated if entorhinal cortex texture can be used in the prediction of the disease development, and according to our results, in many cases, entorhinal cortex texture changes provided better results compared to the hippocampal atrophy, which remains the most frequent method in the assessment of AD. This suggests that the deposition of NFTs in the area of entorhinal cortex may precede the development of atrophy in the hippocampus.

## DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ADNI Data Sharing and Publications Committee. The patients/participants provided their written informed consent to participate in this study.

## AUTHOR CONTRIBUTIONS

SL contributed to the design and implementation of the research and performed the numerical calculations for the suggested

experiment. DL and IM contributed to the statistical analysis. CP supervised the project and contributed to the manuscript preparation and revision. PK read and approved the final submitted version. All authors contributed to the article and approved the submitted version.

## FUNDING

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI was funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen, Bristol-Myers Squibb Company, CereSpir, Inc., Cogstate, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd., and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Assessment of AD using Texture Alzheimer Immunotherapy Research & Development, LLC., Johnson & Johnson Pharmaceutical Research & Development LLC., Lumosity, Lundbeck, Merck & Co., Inc., Meso Scale Diagnostics, LLC., NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research was providing funds to support ADNI clinical sites in Canada.

## ACKNOWLEDGMENTS

Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.



## REFERENCES

- Bakkour, A., Morris, J. C., and Dickerson, B. C. (2009). The cortical signature of prodromal AD. *Neurology* 72, 1048–1055. doi: 10.1212/01.wnl.0000340981.97664.2f
- Berthold, M. R., Cebon, N., Dill, F., Gabriel, T. R., Kötter, T., Meinl, T., et al. (2008). “KNIME: the Konstanz information miner,” in *Data Analysis, Machine Learning and Applications, Studies in Classification, Data Analysis, and Knowledge Organization*, eds C. Preisach, H. Burkhardt, L. Schmidt-Thieme, and R. Decker (Berlin: Springer), 319–326. doi: 10.1007/978-3-540-78246-9\_38
- Bjerke, M., and Engelborghs, S. (2018). Cerebrospinal fluid biomarkers for early and differential Alzheimer's Disease diagnosis. *J. Alzheimers Dis.* 62, 1199–1209. doi: 10.3233/jad-170680
- Blennow, K., and Zetterberg, H. (2018). The past and the future of Alzheimer's Disease fluid biomarkers. *J. Alzheimers Dis.* 62, 1125–1140.
- Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259. doi: 10.1007/bf00308809
- Braak, H., and Braak, E. (1996). Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. *Acta Neuropathol.* 92, 197–201. doi: 10.1007/s004010050508
- Braak, H., and Braak, E. (1997a). Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol. Aging* 18, 351–357. doi: 10.1016/s0197-4580(97)00056-0
- Braak, H., and Braak, E. (1997b). Staging of Alzheimer-related cortical destruction. *Int. Psychogeriatr.* 9(Suppl. 1), 257–261. discussion 269–272. doi: 10.1017/s1041610297004973
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., et al. (2016). Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. *Sci. Transl. Med.* 8:38ra66.
- Busatto, G. F., Garrido, G. E. J., Almeida, O. P., Castro, C. C., Camargo, C. H. P., Cid, C. G., et al. (2003). A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease. *Neurobiol. Aging* 24, 221–231. doi: 10.1016/s0197-4580(02)00084-2
- Chincarini, A., Bosco, P., Calvini, P., Gemme, G., Esposito, M., Olivieri, C., et al. (2011). Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. *Neuroimage* 58, 469–480. doi: 10.1016/j.neuroimage.2011.05.083
- Chupin, M., Géraud, E., Cuingnet, R., Boutet, C., Lemieux, L., Lehericy, S., et al. (2009). Fully automatic hippocampus segmentation and classification in Alzheimer's Disease and mild cognitive impairment applied on data from ADNI. *Hippocampus* 19, 579–587. doi: 10.1002/hipo.20626
- Colliot, O., Chételat, G., Chupin, M., Desgranges, B., Magnin, B., Benali, H., et al. (2008). Discrimination between Alzheimer Disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. *Radiology* 248, 194–201. doi: 10.1148/radiol.2481070876
- Cuingnet, R., Géraud, E., Tessieras, J., Auzias, G., Lehericy, S., Habert, M.-O., et al. (2011). Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. *NeuroImage Mult. Decod. Brain Read.* 56, 766–781. doi: 10.1016/j.neuroimage.2010.06.013
- Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., et al. (2014). Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. *Neuroimage Clin.* 4, 164–173. doi: 10.1016/j.nicl.2013.11.010
- DeLong, E. R., DeLong, D. M., and Clarke-Pearson, D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44, 837–845.
- deToledo-Morrell, L., Stoub, T. R., Bulgakova, M., Wilson, R. S., Bennett, D. A., Leurgans, S., et al. (2004). MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. *Neurobiol. Aging* 25, 1197–1203. doi: 10.1016/j.neurobiolaging.2003.12.007
- Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., De Santi, S., Segal, S., et al. (2007). Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. *Neurology* 68, 828–836. doi: 10.1212/01.wnl.0000256697.20968.d7
- Dickerson, B. C., Goncharova, I., Sullivan, M. P., Forchetti, C., Wilson, R. S., Bennett, D. A., et al. (2001). MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. *Neurobiol. Aging* 22, 747–754. doi: 10.1016/s0197-4580(01)00271-8
- Drummond, E., and Wisniewski, T. (2017). Alzheimer's disease: experimental models and reality. *Acta Neuropathol.* 133, 155–175.
- Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol.* 6, 734–746. doi: 10.1016/s1474-4422(07)70178-3
- Dukart, J., Sambataro, F., and Bertolino, A. (2016). Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers. *J. Alzheimers Dis.* 49, 1143–1159. doi: 10.3233/jad-150570
- Elwood, R. W. (1991). The wechsler memory scale—revised: psychometric characteristics and clinical application. *Neuropsychol. Rev.* 2, 179–201. doi: 10.1007/bf01109053
- Eskildsen, S. F., Coupé, P., García-Lorenzo, D., Fonov, V., Pruessner, J. C., Collins, D. L., et al. (2013). Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. *Neuroimage* 65, 511–521. doi: 10.1016/j.neuroimage.2012.09.058
- Farias, S. T., Mungas, D., Reed, B. R., Harvey, D., and DeCarli, C. (2009). Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. *Arch. Neurol.* 66, 1151–1157.
- Ferrarini, L., Frisoni, G. B., Pievani, M., Reiber, J. H. C., Ganzola, R., Milles, J., et al. (2009). Morphological hippocampal markers for automated detection of Alzheimer's disease and mild cognitive impairment converters in magnetic resonance images. *J. Alzheimers Dis.* 17, 643–659. doi: 10.3233/jad-2009-1082
- Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., et al. (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 33, 341–355.
- Fischl, B., van der Kouwe, A., Destrieux, C., Halgren, E., Ségonne, F., Salat, D. H., et al. (2004). Automatically parcellating the human cerebral cortex. *Cereb. Cortex* 14, 11–22. doi: 10.1093/cercor/bhg087
- Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198.
- Galton, C., Gomez-Anson, B., Antoun, N., Scheltens, P., Patterson, K., Graves, M., et al. (2001). Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. *J. Neurol. Neurosurg. Psychiatry* 70, 165–173. doi: 10.1136/jnnp.70.2.165
- Gao, N., Tao, L.-X., Huang, J., Zhang, F., Li, X., O'Sullivan, F., et al. (2018). Contourlet-based hippocampal magnetic resonance imaging texture features for multivariate classification and prediction of Alzheimer's disease. *Metab. Brain Dis.* 33, 1899–1909. doi: 10.1007/s11011-018-0296-1
- Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., et al. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann. Neurol.* 41, 17–24. doi: 10.1002/ana.410410106
- Haralick, R. M., Shanmugam, K., and Dinstein, I. (1973). Textural features for image classification. *IEEE Trans. Syst. Man Cybernet. SMC* 3, 610–621.
- Hwang, E.-J., Kim, H.-G., Kim, D., Rhee, H. Y., Ryu, C.-W., Liu, T., et al. (2016). Texture analyses of quantitative susceptibility maps to differentiate Alzheimer's disease from cognitive normal and mild cognitive impairment. *Med. Phys.* 43:4718. doi: 10.1118/1.4958959
- Jack, C. R., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Smith, G. E., Ivnik, R. J., et al. (1999). Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. *Neurology* 52, 1397–1403.
- Jack, C. R., Shiung, M. M., Gunter, J. L., O'Brien, P. C., Weigand, S. D., Knopman, D. S., et al. (2004). Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. *Neurology* 62, 591–600. doi: 10.1212/01.wnl.0000110315.26026.ef
- Johnson, K., Sperling, R., Gidicsin, C., Carmasin, J., Maye, J., Coleman, R., et al. (2013). Flortetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. *Alzheimers Dement* 9, S72–S83.
- Juottonen, K., Laakso, M. P., Partanen, K., and Soininen, H. (1999). Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. *AJNR Am. J. Neuroradiol.* 20, 139–144.
- Khan, W., Westman, E., Jones, N., Wahlund, L.-O., Mecocci, P., Vellas, B., et al. (2015). Automated hippocampal subfield measures as predictors of conversion



- from mild cognitive impairment to alzheimer's disease in two independent cohorts. *Brain Topogr.* 28, 746–759. doi: 10.1007/s10548-014-0415-1
- Killiany, R. J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., et al. (2000). Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. *Ann. Neurol.* 47, 430–439. doi: 10.1002/1531-8249(200004)47:4<430::aid-ana5>3.0.co;2-i
- Killiany, R. J., Hyman, B. T., Gomez-Isla, T., Moss, M. B., Kikinis, R., Jolesz, F., et al. (2002). MRI measures of entorhinal cortex vs hippocampus in preclinical AD. *Neurology* 58, 1188–1196. doi: 10.1212/wnl.58.8.1188
- Kitazawa, M., Medeiros, R., and LaFerla, F. M. (2012). transgenic mouse models of Alzheimer Disease: developing a better model as a tool for therapeutic interventions. *Curr. Pharm. Des.* 18, 1131–1147. doi: 10.2174/138161212799315786
- Kordower, J. H., Chu, Y., Stebbins, G. T., DeKosky, S. T., Cochran, E. J., Bennett, D., et al. (2001). Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. *Ann. Neurol.* 49, 202–213. doi: 10.1002/1531-8249(20010201)49:2<202::aid-ana40>3.0.co;2-3
- Leandrou, S., Petroudi, S., Reyes-Aldasoro, C. C., Kyriacou, P. A., and Pattichis, C. S. (2018). Quantitative MRI brain studies in mild cognitive impairment and Alzheimer #x0027;s disease: a methodological review. *IEEE Rev. Biomed. Eng.* 11, 97–111.
- Lee, S., Lee, H., Kim, K. W., and Alzheimer's Disease Neuroimaging Initiative. (2020). Magnetic resonance imaging texture predicts progression to dementia due to Alzheimer disease earlier than hippocampal volume. *J. Psychiatry Neurosci.* 45, 7–14. doi: 10.1503/jpn.180171
- Luk, C. C., Ishaque, A., Khan, M., Ta, D., Chenji, S., Yang, Y.-H., et al. (2018). Alzheimer's disease: 3-Dimensional MRI texture for prediction of conversion from mild cognitive impairment. *Alzheimers Dement* 10, 755–763. doi: 10.1016/j.dadm.2018.09.002
- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E. M., et al. (1984). Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA work group\* under the auspices of department of health and human services task force on Alzheimer's Disease. *Neurology* 34, 939–939. doi: 10.1212/wnl.34.7.939
- Misra, C., Fan, Y., and Davatzikos, C. (2009). Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. *Neuroimage* 44, 1415–1422. doi: 10.1016/j.neuroimage.2008.10.031
- Mitchell, A. J., and Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. *Acta Psychiatr. Scand.* 119, 252–265. doi: 10.1111/j.1600-0447.2008.01326.x
- Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 43, 2412–2414.
- Morris, J. C., Storandt, M., McKeel, D. W. Jr., Rubin, E. H., Price, J. L., Grant, E. A., et al. (1996). Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer's disease. *Neurology* 46, 707–719. doi: 10.1212/wnl.46.3.707
- Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., et al. (2008). Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment. Alzheimer's disease, and other dementias. *J. Nucl. Med.* 49, 390–398. doi: 10.2967/jnumed.107.045385
- Mueller, S. G., Schuff, N., Yaffe, K., Madison, C., Miller, B., Weiner, M. W., et al. (2010). Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. *Hum. Brain Mapp.* 31, 1339–1347. doi: 10.1002/hbm.20934
- Pennanen, C., Kivipelto, M., Tuomainen, S., Hartikainen, P., Hänninen, T., Laakso, M. P., et al. (2004). Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. *Neurobiol. Aging* 25, 303–310. doi: 10.1016/s0197-4580(03)00084-8
- Petrella, J. R., Coleman, R. E., and Doraiswamy, P. M. (2003). Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. *Radiology* 226, 315–336. doi: 10.1148/radiol.2262011600
- Plant, C., Teipel, S. J., Oswald, A., Böhm, C., Meindl, T., Mourao-Miranda, J., et al. (2010). Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. *Neuroimage* 50, 162–174. doi: 10.1016/j.neuroimage.2009.11.046
- Ryu, S. Y., Lim, E. Y., Na, S., Shim, Y. S., Cho, J. H., Yoon, B., et al. (2017). Hippocampal and entorhinal structures in subjective memory impairment: a combined MRI volumetric and DTI study. *Int. Psychogeriatr.* 29, 785–792. doi: 10.1017/s1041610216002349
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., et al. (2014). Single App knock-in mouse models of Alzheimer's disease. *Nat. Neurosci.* 17, 661–663. doi: 10.1038/nn.3697
- Scahill, R. I., Schott, J. M., Stevens, J. M., Rossor, M. N., and Fox, N. C. (2002). Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. *Proc. Natl. Acad. Sci. U.S.A.* 99, 4703–4707. doi: 10.1073/pnas.052587399
- Simoes, R., Slump, C., and Cappellen van Walsum, A.-M. (2012). “Using local texture maps of brain MR images to detect mild cognitive impairment,” in *2012 21st International Conference on Pattern Recognition (ICPR)*, Tsukuba, 153–156.
- Sled, J. G., Zijdenbos, A. P., and Evans, A. C. (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE Trans. Med. Imaging* 17, 87–97. doi: 10.1109/42.668698
- Sørensen, L., Igel, C., Liv Hansen, N., Osler, M., Lauritzen, M., Rostrup, E., et al. (2015). Early detection of Alzheimer's disease using MRI hippocampal texture. *Hum Brain Mapp.* 37, 1148–1161. doi: 10.1002/hbm.23091
- Squire, L. R., Stark, C. E. L., and Clark, R. E. (2004). The medial temporal lobe. *Annu. Rev. Neurosci.* 27, 279–306.
- Tapiola, T., Pennanen, C., Tapiola, M., Tervo, S., Kivipelto, M., Hänninen, T., et al. (2008). MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. *Neurobiol. Aging* 29, 31–38. doi: 10.1016/j.neurobiolaging.2006.09.007
- Wolz, R., Julkunen, V., Koikkalainen, J., Niskanen, E., Zhang, D. P., Rueckert, D., et al. (2011). Multi-method analysis of MRI images in early diagnostics of Alzheimer's Disease. *PLoS One* 6:e0025446.
- Zhang, J., Yu, C., Jiang, G., Liu, W., and Tong, L. (2012). 3D texture analysis on MRI images of Alzheimer's disease. *Brain Imaging Behav.* 6, 61–69. doi: 10.1007/s11682-011-9142-3
- Zhou, M., Zhang, F., Zhao, L., Qian, J., and Dong, C. (2016). Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease. *Rev. Neurosci.* 27, 185–195.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Leandrou, Lamnisos, Mamais, Kyriacou and Pattichis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.